Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

The RIO-Diabetes study, which was performed in 159 centers in 11 countries, showed that rimonabant 20 mg once daily can reduce body weight and improve cardiovascular and metabolic risk factors in ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Nissen and colleagues investigated whether treatment with one such CB1 antagonist, rimonabant, could slow the progression of coronary atherosclerosis in obese patients with the metabolic syndrome.

The results from the study showed that the patients taking the higher dose of rimonabant lost more weight after one year than those who had taken a placebo. As in the animal studies, rimonabant ...

Curioni C and André C (2006) Rimonabant for overweight or obesity. The Cochrane Database of Systematic Reviews, Issue 4, Art. No CD006162.pub2 Rimonabant is the only drug currently under ...

“There’s a really fascinating story involving the drug rimonabant,” Wenk said. “Many years ago, researchers thought if the munchies are due to THC stimulating feeding receptors and ...

CB1 receptor antagonists, such as the aforementioned rimonabant and taranabant, were found to regulate food intake and adipose tissue metabolism, resulting in weight loss and favorable blood lipid ...

丹麦制药公司诺和诺德（Novo Nordisk A/S）周五报告称，该公司下一代减肥药之一monlunabant在较高剂量时减重效果有限，而且有一定副作用，导致该公司股价周五下跌。

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN ...

CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach ...